Gb Virus C Infection is Associated with a Reduced Rate of Reactivation of Latent HIV and Protection against Activation-Induced T-Cell Death

Stapleton J.T. GB virus type C/hepatitis G virus. Semin Liver Dis 2003; 23: 137–148.

Mohr E.L. , Stapleton J.T. GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat 2009; 16: 757–768.

Heringlake S. , Ockenga J. , Tillmann H.L. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis 1998; 177: 1723–1726.

Toyoda H. , Fukuda Y. , Hayakawa T. , Takamatsu J. , Saito H. Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 209–213.

Lefrère J.J. , Ferec C. , Roudot-Thoraval F. GBV-C/ hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. J Med Virol 1999; 59: 32–37.

Yeo A.E. , Matsumoto A. , Hisada M. , Shih J.W. , Alter H.J. , Goedert J.J. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132: 959–963.

Tillmann H.L. , Heiken H. , Knapik-Botor A. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345: 715–724.

Xiang J. , Wunschmann S. , Diekema D.J. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345: 707–714.

Nunnari G. , Nigro L. , Palermo F. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139: 26–30.

Williams C.F. , Klinzman D. , Yamashita T.E. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350: 981–990.

Badley A.D. , Parato K. , Cameron D.W. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999; 6: 420–432.

Alimonti J.B. , Ball T.B. , Fowke K.R. Mechanisms of CD4⁺ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003; 84: 1649–1661.

Hunt P.W. , Martin J.N. , Sinclair E. T cell activation is associated with lower CD4⁺ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534–1543.

Grossman Z. , Meier-Schellersheim M. , Paul W.E. , Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12: 289–295.

Moir S. , Fauci A.S. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235–245.

Giorgi J.V. , Hultin L.E. , McKeating J.A. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859–870.

Hazenberg M.D. , Otto S.A. , van Benthem B.H. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881–1888.

Dockrell D.H. , Badley A.D. , Algeciras-Schimnich A. Activation-induced CD4⁺ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4⁺ T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses 1999; 15: 1509–1518.

Geeraert L. , Kraus G. , Pomerantz R.J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59: 487–501.

Siliciano J.D. , Kajdas J. , Finzi D. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4⁺ T cells. Nat Med 2003; 9: 727–728.

Dornadula G. , Zhang H. , VanUitert B. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 1627–1632.

Palmer S. , Maldarelli F. , Wiegand A. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 3879–3884.

Rong L. , Perelson A.S. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Comput Biol 2009; 5: e1000533.

Günthard H.F. , Wong J.K. , Spina C.A. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181: 522–531.

Tobin N.H. , Learn G.H. , Holte S.E. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79: 9625–9634.

Wolschendorf F. , Duverger A. , Jones J. Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010; 84: 8712–8720.

Stevenson M. , Stanwick T.L. , Dempsey M.P. , Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9: 1551–1560.

Copeland K.F. Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem 2005; 5: 1093–1101.

Maidana-Giret M.T. , Silva T.M. , Sauer M.M. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 2009; 23: 2277–2287.

Stapleton J.T. , Chaloner K. , Zhang J. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 2009; 23: 605–610.

Rodriguez B. , Woolley I. , Lederman M.M. , Zdunek D. , Hess G. , Valdez H. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187: 504–507.

Souza I.E. , Zhang W. , Diaz R.S. , Chaloner K. , Klinzman D. , Stapleton J.T. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians. HIV Med 2006; 7: 25–31.

Antonucci G. , Girardi E. , Cozzi-Lepri A. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther 2005; 10: 109–117.

George S.L. , Xiang J. , Stapleton J.T. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 2003; 316: 191–201.

Xiang J. , Klinzman D. , McLinden J. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 1998; 72: 2738–2744.

Xiang J. , George S.L. , Wunschmann S. , Chang Q. , Klinzman D. , Stapleton J.T. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363: 2040–2046.

Coiras M. , Lopez-Huertas M.R. , Perez-Olmeda M. , Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798–812.

Wang F.X. , Xu Y. , Sullivan J. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128–137.

George S.L. , Varmaz D. , Stapleton J.T. GB virus C replicates in primary T and B lymphocytes. J Infect Dis 2006; 193: 451–454.

Moenkemeyer M. , Schmidt R.E. , Wedemeyer H. , Tillmann H.L. , Heiken H. GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. J Med Virol 2008; 80: 1933–1940.